- About Us
- Our Clients
- Our Expertise
- Our People
- Global Services
- Students
- Careers
- News
- Contact Us
19 November 2013
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today announced the closing of the full overallotment option to purchase an additional 562,500 shares at a price of $8.00 per share granted to the underwriters in connection with Tekmira’s previously completed public offering of common stock, increasing the total gross proceeds to US$34.5 million.
Tekmira was represented by Farris LLP, with a team lead by Hector MacKay-Dunn, Q.C. that included Peter Roth and James Campbell.
To view the full press release, please click here.
Sign up for our Email Newsletter to receive regular Farris updates: